MedTrace Logo

GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

NCT05010694 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-07-08

No results posted yet for this study

Summary

Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid tumors.

Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in patients with KRAS mutant advanced solid tumors.

Conditions

  • Advanced Solid Tumors Harboring With G12C Mutation

Interventions

DRUG

GH35 Tablet

GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.

Sponsors & Collaborators

  • Suzhou Genhouse Bio Co., Ltd.

    lead OTHER

Principal Investigators

  • Baohui Han, Professor · Shanghai Chest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2023-03-22
Completion
2025-12-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010694 on ClinicalTrials.gov